Differentiating Between Unbranded Biologics and Biosimilars
Differences between biologics – both branded and unbranded – and biosimilars are explored by Dr Karara.
EP: 1.Overview and Prevalence of Biologics
EP: 2.Defining Unbranded Biologics
EP: 3.Clinical Impacts of Biologics on Patient Quality of Care
EP: 4.Pipeline Development and Future Implications of Unbranded Biologics
EP: 5.Emphasizing Biologics Space as Payer Priority
EP: 6.Evolving Complexity of Biologics Space
EP: 7.Differentiating Between Unbranded Biologics and Biosimilars
EP: 8.The Impact of Unbranded Biologics in the Evolving Treatment Landscape of Autoimmune Disease
EP: 9.Implications of Multiple Switching with Biologic Therapies
EP: 10.Factors Affecting Biologics Affordability for Patient Treatment
EP: 11.Pipeline Development Outlook and Future Implications of Unbranded Biologics and Biosimilars
Kareem Karara, PharmD, BCPS, CCHP: An interchangeable biosimilar is a biosimilar that can be substituted for the reference product without the intervention of the health care provider who prescribed the reference product. An interchangeable biosimilar is a biologic product that’s biosimilar to the reference product. It can be expected to produce the same clinical result as the reference product in any given patient. For products that are administered more than once—chronic therapies—the risk in terms of safety or diminished efficacy in alternating or switching between the product and its reference product isn’t any greater than the risk of using the reference product without switching at all. For an interchangeable biosimilar, the FDA is going to require specific switch studies to show that it’s interchangeable.
An unbranded biologic differs from a biosimilar in the following ways: An unbranded biologic is essentially a branded biologic without the brand name on the label, but a biosimilar is different. A biosimilar is highly similar to the reference product, the branded biologic, notwithstanding any minor differences in clinically inactive components of the medication. There are no clinically meaningful differences between the biologic product and the reference product in terms of safety, purity, and potency.
Transcript edited for clarity.
FDA Drafts Rules for Fair Biosimilar Promotion
June 11th 2024An updated draft guidance says that promotional materials that suggest a biosimilar or reference product is superior “are likely to be false or misleading.” The agency has also warned against making comparisons between biosimilars and those with the interchangeable designation.
Read More
